Altimmune, Inc. (NASDAQ:ALT) Receives $20.83 Consensus Price Target from Analysts

Shares of Altimmune, Inc. (NASDAQ:ALT) have received an average recommendation of “Moderate Buy” from the nine brokerages that are covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $20.83.

Several equities research analysts have issued reports on ALT shares. Stifel Nicolaus started coverage on Altimmune in a report on Wednesday, January 8th. They set a “buy” rating and a $18.00 price target for the company. UBS Group started coverage on Altimmune in a report on Tuesday, November 12th. They set a “buy” rating and a $26.00 price target for the company. William Blair started coverage on Altimmune in a report on Friday, February 28th. They set a “market perform” rating for the company. Finally, HC Wainwright reaffirmed a “buy” rating and set a $12.00 price target on shares of Altimmune in a report on Monday.

Altimmune Trading Down 0.5 %

NASDAQ:ALT opened at $5.96 on Wednesday. Altimmune has a 1-year low of $5.28 and a 1-year high of $11.77. The firm has a fifty day simple moving average of $6.78 and a 200 day simple moving average of $7.19. The stock has a market capitalization of $423.91 million, a PE ratio of -3.85 and a beta of 0.19.

Altimmune (NASDAQ:ALT) last released its earnings results on Thursday, February 27th. The company reported ($0.33) earnings per share for the quarter, beating the consensus estimate of ($0.34) by $0.01. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. The business had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.00 million. On average, equities analysts predict that Altimmune will post -1.35 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Altimmune

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Ameriprise Financial Inc. lifted its holdings in shares of Altimmune by 35.6% during the fourth quarter. Ameriprise Financial Inc. now owns 5,254,898 shares of the company’s stock worth $37,888,000 after buying an additional 1,378,854 shares in the last quarter. Geode Capital Management LLC raised its stake in Altimmune by 4.7% in the third quarter. Geode Capital Management LLC now owns 1,668,004 shares of the company’s stock valued at $10,244,000 after purchasing an additional 74,194 shares in the last quarter. Bellevue Group AG raised its stake in Altimmune by 9.5% in the fourth quarter. Bellevue Group AG now owns 945,446 shares of the company’s stock valued at $6,817,000 after purchasing an additional 81,786 shares in the last quarter. Northern Trust Corp raised its stake in Altimmune by 5.7% in the fourth quarter. Northern Trust Corp now owns 665,916 shares of the company’s stock valued at $4,801,000 after purchasing an additional 35,918 shares in the last quarter. Finally, Two Sigma Investments LP raised its stake in Altimmune by 33.2% in the fourth quarter. Two Sigma Investments LP now owns 605,303 shares of the company’s stock valued at $4,364,000 after purchasing an additional 151,001 shares in the last quarter. Institutional investors and hedge funds own 78.05% of the company’s stock.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.